# Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

> **NCT00242385** · PHASE1 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 25 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **BIOLOGICAL:** Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
- **BIOLOGICAL:** Dose of 60 mg/kg alpha1-proteinase inhibitor

## Key facts

- **NCT ID:** NCT00242385
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-20
- **Primary completion:** 2006-06-05
- **Final completion:** 2006-06-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242385, "Pharmacokinetic Study of ARALAST (Human Alpha1- PI)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00242385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*